177 related articles for article (PubMed ID: 15144904)
1. An intron promotes the anti-bcr-abl activities of a retrovirally expressed ribozyme in chronic myeloid leukemia cells.
Liu JH; Wu SC; Chen WS; Yen CC; Yang MH; Tsai YC; Chen PM
Biochem Biophys Res Commun; 2004 Jun; 318(3):764-72. PubMed ID: 15144904
[TBL] [Abstract][Full Text] [Related]
2. Purging of chronic myelogenous leukemia cells by retrovirally expressed anti-bcr-abl ribozymes with specific cellular compartmentalization.
Mendoza-Maldonado R; Zentilin L; Fanin R; Giacca M
Cancer Gene Ther; 2002 Jan; 9(1):71-86. PubMed ID: 11916246
[TBL] [Abstract][Full Text] [Related]
3. [The effect of anti-bcr-abl hammerhead ribozyme on bone marrow purging].
Wu Y; Chen YZ; Huang HF; Chen P; Lu LH
Sheng Wu Hua Xue Yu Sheng Wu Wu Li Xue Bao (Shanghai); 2003 Sep; 35(9):859-63. PubMed ID: 12958661
[TBL] [Abstract][Full Text] [Related]
4. [Construction of retrovirus vector of bcr/abl mRNA cleaving ribozyme gene and its effects on K562 cells].
Wu Y; Chen Y; Hu J
Zhonghua Xue Ye Xue Za Zhi; 1998 Dec; 19(12):623-6. PubMed ID: 11263328
[TBL] [Abstract][Full Text] [Related]
5. Ribozyme-mediated cleavage of the bcr/abl transcript expressed in chronic myeloid leukemia.
Wright L; Wilson SB; Milliken S; Biggs J; Kearney P
Exp Hematol; 1993 Dec; 21(13):1714-8. PubMed ID: 8243570
[TBL] [Abstract][Full Text] [Related]
6. Ribozyme-mediated cleavage of the BCRABL oncogene transcript: in vitro cleavage of RNA and in vivo loss of P210 protein-kinase activity.
Shore SK; Nabissa PM; Reddy EP
Oncogene; 1993 Nov; 8(11):3183-8. PubMed ID: 8414522
[TBL] [Abstract][Full Text] [Related]
7. Cleavage of BCR/ABL mRNA by synthetic ribozymes--effects on the proliferation rate of K562 cells.
Lange W
Klin Padiatr; 1995; 207(4):222-4. PubMed ID: 7564157
[TBL] [Abstract][Full Text] [Related]
8. Investigating and improving the specificity of ribozymes directed against the bcr-abl translocation.
James H; Mills K; Gibson I
Leukemia; 1996 Jun; 10(6):1054-64. PubMed ID: 8667643
[TBL] [Abstract][Full Text] [Related]
9. [Study on the in vitro cleavage abilities of ribozymes specific to different sites of bcr-abl fusion gene and their induction of apoptosis in K562 cells].
Feng Q; Sun B; Zhao Y
Zhonghua Yi Xue Za Zhi; 2000 Feb; 80(2):127-30. PubMed ID: 11798747
[TBL] [Abstract][Full Text] [Related]
10. Triptolide inhibits Bcr-Abl transcription and induces apoptosis in STI571-resistant chronic myelogenous leukemia cells harboring T315I mutation.
Shi X; Jin Y; Cheng C; Zhang H; Zou W; Zheng Q; Lu Z; Chen Q; Lai Y; Pan J
Clin Cancer Res; 2009 Mar; 15(5):1686-97. PubMed ID: 19240172
[TBL] [Abstract][Full Text] [Related]
11. Gene therapy for BCR-ABL+ human CML with dual phosphorylation resistant p27Kip1 and stable RNA interference using an EBV vector.
Sengupta A; Banerjee D; Chandra S; Banerjee S
J Gene Med; 2006 Oct; 8(10):1251-61. PubMed ID: 16952195
[TBL] [Abstract][Full Text] [Related]
12. Antisense inhibition of P210 bcr-abl in chronic myeloid leukemia.
Vaerman JL; Lewalle P; Martiat P
Stem Cells; 1993 Oct; 11 Suppl 3():89-95. PubMed ID: 8298481
[TBL] [Abstract][Full Text] [Related]
13. Stable RNA interference (RNAi) as an option for anti-bcr-abl therapy.
Scherr M; Battmer K; Schultheis B; Ganser A; Eder M
Gene Ther; 2005 Jan; 12(1):12-21. PubMed ID: 15602589
[TBL] [Abstract][Full Text] [Related]
14. [Effects of anti-ABL tyrosine kinase intrabody on the growth of K562 cells in nude mice].
Xu D; Song JM; Hu Y; Guo H; Cao DJ; Wang P; Liu H; Zhao CH
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2002 Feb; 24(1):11-4. PubMed ID: 12905832
[TBL] [Abstract][Full Text] [Related]
15. Comparison of activities between hammerhead ribozymes and DNA enzymes targeted to L6 BCR-ABL chimeric (b2a2) mRNA.
Warashina M; Kuwabara T; Taira K
Nucleic Acids Symp Ser; 1997; (37):213-4. PubMed ID: 9586075
[TBL] [Abstract][Full Text] [Related]
16. Second case of CML with aberrant BCR-ABL fusion transcript (e8/a2) with insertion of an inverted ABL intron 1b sequence.
Sugimoto T; Ijima K; Hisatomi H; Murayama T; Mizuno I; Hato A; Imoto S; Nishimura R; Koizumi T
Am J Hematol; 2004 Oct; 77(2):164-6. PubMed ID: 15389825
[TBL] [Abstract][Full Text] [Related]
17. [Effect of specific siRNA targeting against bcr-abl chimeric gene on chronic myelogenous leukemia cells].
Wang S; Chai YB; Liu F; Zhang XY; Jia W; Xie X; Yu WQ; Shang ZC; Jin BQ; Sun BZ
Zhonghua Yi Xue Za Zhi; 2005 Jan; 85(3):198-202. PubMed ID: 15854468
[TBL] [Abstract][Full Text] [Related]
18. Improved specificity of ribozyme-mediated cleavage of bcr-abl mRNA.
Kearney P; Wright LA; Milliken S; Biggs JC
Exp Hematol; 1995 Aug; 23(9):986-9. PubMed ID: 7543419
[TBL] [Abstract][Full Text] [Related]
19. A sequential blockade strategy for the design of combination therapies to overcome oncogene addiction in chronic myelogenous leukemia.
Chen R; Gandhi V; Plunkett W
Cancer Res; 2006 Nov; 66(22):10959-66. PubMed ID: 17108134
[TBL] [Abstract][Full Text] [Related]
20. Ex vivo effects associated with the expression of a bcr-abl-specific ribozyme in a CML cell line.
Wright LA; Milliken S; Biggs JC; Kearney P
Antisense Nucleic Acid Drug Dev; 1998 Feb; 8(1):15-23. PubMed ID: 9512092
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
